Multiple synchronous primary lung adenocarcinomas with distinct epidermal growth factor receptor mutations: A case report
An 83-year-old woman presents with two synchronous primary lung adenocarcinomas each harboring unique EGFR mutations, one classical and the other rare. She was treated with adjuvant Osimertinib following surgical lobectomy and remains well 44 months from the time of her diagnosis. Her case demonstra...
Main Authors: | Matthew Siskin, Joshua K. Sabari |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-09-01
|
Series: | Current Problems in Cancer: Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621922000357 |
Similar Items
-
EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report
by: Xinyu von Buttlar, MD, MS, et al.
Published: (2021-06-01) -
Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report
by: Fei Ren, et al.
Published: (2022-08-01) -
Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review)
by: O.M. Smorodska, et al.
Published: (2021-06-01) -
Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
by: Fionnuala Crowley, MB BCh BAO, et al.
Published: (2022-01-01) -
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review
by: Alessandro Leonetti, et al.
Published: (2021-04-01)